U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07208149) titled 'A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)' on Sept. 19.
Brief Summary: This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.
Study Start Date: Oct. 17
Study Type: INTERVENTIONAL
Condition:
Triple-Negative Breast Cancer (TNBC)
Intervention:
DRUG: MR001 Bispecific Antibody for Injection
Intravenous infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shenzhen Majory Biotechnology Co., Ltd.
...